ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Aligos Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$4.84−0.02 (-0.41%)

Close on Oct 19, 2026

Market cap: $50.49M
P/E (TTM): –
Dividend yield: –

Aligos Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	2.19	3.61	6.19	0	0	0	–
Research & Development	69	70	73	85	104	80	44
General & Administrative	21	23	31	26	29	18	10
Operating Expenses	90	93	104	111	133	98	54
Operating Income	-88	-89	-88	-98	-128	-98	-54
Asset Impairment Charges	0	0	0	0	0	0	0
Gain (Loss) on Investments	–	–	–	-0.06	-0.11	0.07	–
Gain (Loss) on Sale of Assets	–	–	-0.02	–	–	–	–
Pretax Income	-24	-131	-87	-96	-128	-108	-52
Income Tax Expense	0.31	0.33	0.80	0.11	0.14	0.16	0.09
Net Income	-24	-131	-88	-96	-128	-109	-52
EPS (Basic)(per share)	-2.45	-20.94	-34.20	-56.25	-80.50	-271.75	-651.00
EPS (Diluted)(per share)	-2.45	-20.94	-34.20	-56.25	-80.50	-271.75	-651.00
Shares Outstanding (Basic, Weighted)(shares)	9.88	6.26	2.56	1.71	1.59	0.40	0.08
Shares Outstanding (Diluted, Weighted)(shares)	9.88	6.26	2.56	1.71	1.59	0.40	0.08
Net Interest Income	2.20	1.70	4.30	1.50	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2112.1%
Net margin: -2031.1%
Return on equity, FY2025: -196.9%

Financial strength

Current ratio: 2.19
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 107.2%

Valuation

P/E ratio: –
Price to sales: 13.50
Price to book: 1.58
Dividend yield: –